Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Confo Therapeutics N.V.

Headquarters: Ghent, Belgium
Year Founded: 2015
Status: Private

BioCentury | Feb 12, 2025
Discovery & Translation

Pain targets in ion channel pathways: an Innovation Distillery spotlight

Upstream regulators of ion channel expression or function are an emerging frontier for novel pain targets
BioCentury | Sep 13, 2024
Data Byte

PanTera largest Belgian A round to date

Only nine other biotechs have raised over $25 million since 2015
BioCentury | Aug 7, 2024
Emerging Company Profile

Diagonal: Gluing receptor complexes back together

Newco uses AI/ML to find bispecific antibodies that can reassemble functional receptor complexes in the face of mutations
BioCentury | Aug 1, 2024
Finance

Venture Report: venBio closes new $528M fifth fund

Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers
BioCentury | Sep 13, 2023
Management Tracks

CEO Nick Leschly shifting to chair as 2seventy bio restructures

Plus: CFO Galá promoted at Jazz, and updates from Geron, Mirum, ReNAgade, 
BioCentury | Aug 29, 2023
Management Tracks

Crossover-backed Arbor names Tamboli CFO

Plus: Atkinson named chief technical operations officer at Vertex, and updates from Confo, Flagship, Citryll and more
BioCentury | Aug 1, 2023
Deals

Pharma deals seek novelty with heavy focus on first in class

An analysis of the products, technologies and targets that have attracted global pharma deals over past 12 months
BioCentury | Mar 31, 2023
Product Development

March 31 Quick Takes: Cytokinetics to discontinue reldesemtiv ALS Phase III

Plus: Zealand raises $216.4M and updates from Confo, Daiichi and SineuGene
BioCentury | Mar 2, 2023
Deals

Lilly adds to clinical pain pipeline via deal with Belgium’s Confo

Private European company gets $40M up front for AGTR2-targeting small molecule in Phase I; deal also includes preclinical antibody
BioCentury | Feb 11, 2021
Finance

Belgium’s V-Bio looking for bigger bets in and out of its home country with

Firm seeks to groom management teams returning to start-ups
Items per page:
1 - 10 of 25